This announcement is a separate document:
サンバイオ：「アクーゴ(R)脳内移植用注」について、TBIに伴う慢性期の運動麻痺の改善治療薬として条件及び期限付き製造販売承認を取得
SanBio: Obtained conditional and time-limited manufacturing and marketing approval as a therapeutic drug for improving motor paralysis in the chronic phase after TBI for Acuogo (R) intracerebral transplantation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.